MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been given a consensus recommendation of “Hold” by the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $23.0769.

MLTX has been the subject of several recent research reports. Oppenheimer upped their price objective on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Needham & Company LLC boosted their target price on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. BTIG Research restated a “buy” rating and issued a $30.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday, March 30th. Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $12.00 to $40.00 in a research note on Thursday, March 19th. Finally, UBS Group set a $24.00 price target on shares of MoonLake Immunotherapeutics in a report on Friday, January 9th.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total value of $62,962,500.00. Following the sale, the director owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. The trade was a 78.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Da Silva Jorge Santos sold 98,127 shares of the stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $18.41, for a total value of $1,806,518.07. Following the completion of the sale, the chief executive officer directly owned 2,976,766 shares of the company’s stock, valued at approximately $54,802,262.06. The trade was a 3.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 3,900,000 shares of company stock valued at $65,714,663. 12.02% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cormorant Asset Management LP increased its position in MoonLake Immunotherapeutics by 118.4% during the 4th quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company’s stock valued at $57,405,000 after purchasing an additional 2,361,260 shares during the period. Janus Henderson Group PLC lifted its position in shares of MoonLake Immunotherapeutics by 18,782.8% in the 4th quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock worth $27,657,000 after purchasing an additional 2,084,888 shares during the period. Logos Global Management LP acquired a new position in shares of MoonLake Immunotherapeutics in the 4th quarter worth approximately $23,065,000. Vivo Capital LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $13,180,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at $6,922,000. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Trading Up 4.1%

Shares of MLTX stock opened at $17.70 on Friday. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The stock’s fifty day simple moving average is $17.49 and its 200 day simple moving average is $15.13. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $1.27 billion, a P/E ratio of -5.03 and a beta of 1.01.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, meeting the consensus estimate of ($0.92). During the same period in the prior year, the company earned ($0.72) earnings per share. As a group, sell-side analysts predict that MoonLake Immunotherapeutics will post -3.42 EPS for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.